Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
Pliant Therapeutics (PLRX, Financials) shares tumbled 58.8% to $3.21 as of 12:40 p.m. ET on Monday, following a 34.8% decline on Friday, after the company announced a voluntary pause in enrollment and dosing for its BEACON-IPF Phase 2b trial.
Warning! GuruFocus has detected 3 Warning Signs with PLRX.
The independent Data Safety Monitoring Board of the trial is cited as the reason for the choice.
The suspension, according to the business, will provide time for data assessment and DSMB justification understanding. The study will remain blinded in order to maintain its integrity; patients already enrolled in it will stay in the experiment. Pliant is now alerting worldwide regulatory authorities and has alerted clinical trial investigators.
Targeting ?v?6 and ?v?1 integrins, proteins linked in fibrosis, Bexotegrast is an oral small-molecule inhibitor being studied. The U.S. Food and Drug Administration has assigned it Fast Track and Orphan Drug designations; the European Medicines Agency has assigned it Orphan Drug status. The BEACON-IPF study is assessing the medication as a possible therapy for the progressive lung illness known as idiopathic pulmonary fibrosis, for which there are few therapeutic choices.
Pliant said it is still dedicated to working with authorities and the DSMB to decide the best course ahead, but it did not provide a restarting enrollment timetable. As additional data becomes available, the business said it would provide updates.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Oscar Health Explodes Higher -- Is This the Market's Next Meme Stock?
June 20 - Oscar Health (NYSE:OSCR) surged more than 18% on Friday, lifting its five-day gain to about 60%, as traders flagged strong momentum indicators and retail interest building around the stock. The rally follows investor commentary on social media, including a post from Ruth Capital highlighting the company's fundamentals. The firm noted Oscar Health's first-quarter performance, which included free cash flow of around $1 billion, as a sign of underlying strength. Traders also pointed to possible indirect political ties, with Oscar Health's co-founder Joshua Kushner being the brother of Jared Kushner, who served in the Trump administration. Market watchers say this connection has drawn attention from retail investors during an election year. Technical signals have added fuel to the stock's run. The moving average convergence divergence, or MACD, remained above its signal line with a positive histogram reading, while the stock price traded above both short- and long-term averages. However, the relative strength index hovered just below 71, indicating the stock may be overbought in the short term. Ruth Capital also warned that heavy reliance on government-backed health programs and earnings volatility could impact performance. Oscar Health shares have climbed nearly 64% so far in 2025 but remain only modestly higher over the past year. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Oscar Health Explodes Higher -- Is This the Market's Next Meme Stock?
June 20 - Oscar Health (NYSE:OSCR) surged more than 18% on Friday, lifting its five-day gain to about 60%, as traders flagged strong momentum indicators and retail interest building around the stock. The rally follows investor commentary on social media, including a post from Ruth Capital highlighting the company's fundamentals. The firm noted Oscar Health's first-quarter performance, which included free cash flow of around $1 billion, as a sign of underlying strength. Traders also pointed to possible indirect political ties, with Oscar Health's co-founder Joshua Kushner being the brother of Jared Kushner, who served in the Trump administration. Market watchers say this connection has drawn attention from retail investors during an election year. Technical signals have added fuel to the stock's run. The moving average convergence divergence, or MACD, remained above its signal line with a positive histogram reading, while the stock price traded above both short- and long-term averages. However, the relative strength index hovered just below 71, indicating the stock may be overbought in the short term. Ruth Capital also warned that heavy reliance on government-backed health programs and earnings volatility could impact performance. Oscar Health shares have climbed nearly 64% so far in 2025 but remain only modestly higher over the past year. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Netflix's 40% Rally Spurs Top Target Hike
Netflix (NASDAQ:NFLX) has been on a tear this year, up roughly 40% thanks to a killer Q1, healthy subscriber adds and the growing appeal of its cheaper, ad-supported tier. Pivotal's four-star analyst Jeff Wlodarczak clearly likes what he sees: he bumped his price objective from $1,350 to $1,600, which still leaves about 24% upside if Netflix hits that mark. What's his logic? First, Netflix's brand and massive library remain unrivaledthink of them as the crown jewels that keep folks hooked. Second, there's plenty of room left abroad. Even though Netflix is already in nearly every country, emerging markets haven't been fully tapped yet. Wlodarczak expects big subscriber gains there over the long haul. He also pointed out how the ad-tier adds a value play: it brings in price-sensitive viewers and lifts average revenue per user without breaking the bank. And yes, there's that eyebrow-raising $1 trillion market-cap goal for 2030. It sounds ambitious, but Pivotal argues that consistent execution and global expansion could get Netflix there. This article first appeared on GuruFocus. Sign in to access your portfolio
